PMID- 32862597
OWN - NLM
STAT- MEDLINE
DCOM- 20210209
LR  - 20210209
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 25
IP  - 3
DP  - 2020 May-Jun
TI  - Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in 
      human lung cancer.
PG  - 1504-1511
AB  - PURPOSE: In the present investigation the hydrophilic drug doxorubicin (DOX) was 
      successfully incorporated with the drug carrier GE11 which serves as marker for 
      tumor cells in non small cell lung cancer(NSCLC) to form the liposomal 
      formulation. METHODS: The formulation was fabricated in two steps: one being the 
      preparation of liposomal formulation using reverse phase evaporation method and 
      second is synthesis of DSPE-PEG 2000 - GE 11complex. RESULTS: Thus prepared 
      liposomes when evaluated via scanning electron spectroscopy showed smooth and 
      spherical surface with particle size ranging between 102+/-0.3 to 120+/-0.5 nm. The 
      percent encapsulation efficiency was 65.34 with highest drug release of 98% up to 
      45 h. The cytotoxic study revealed the non-toxic nature of carrier protein (i.e. 
      GE11). The microbiological study has shown the antibiotic efficiency of liposomal 
      formulation to be comparable with pure drug. In vivo cellular uptake study showed 
      efficiency of GE11 protein in accumulation in tumor cells. The study conducted in 
      mice showed more reduction in tumor size with liposomal formulation (312 mm3) 
      than with pure drug (540 mm3). CONCLUSION: DOX loaded liposomes with GE11 as 
      carriers were successfully formulated by using reverse phase evaporation method. 
      The prepared liposomal formulation was found to be most effective in combating 
      cancer cells when compared to pure drug.
FAU - Guo, Yuehui
AU  - Guo Y
AD  - Department of Intervention, Shanghai Pudong New Area Gongli Hospital, Shanghai, 
      200135, China.
FAU - Zhu, Qingyun
AU  - Zhu Q
FAU - Shi, Jing
AU  - Shi J
FAU - Li, Yanxiang
AU  - Li Y
FAU - Fu, Daiquan
AU  - Fu D
FAU - Qiao, Delin
AU  - Qiao D
FAU - Chen, Shiwei
AU  - Chen S
FAU - Yang, Yuwei
AU  - Yang Y
FAU - Wang, Yane
AU  - Wang Y
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 
      2000))
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (GE11 peptide)
RN  - 0 (Liposomes)
RN  - 0 (Peptides)
RN  - 0 (Phosphatidylethanolamines)
RN  - 0 (liposomal doxorubicin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/pharmacology
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Cell Line, Tumor
MH  - Doxorubicin/*analogs & derivatives/chemistry/*pharmacology
MH  - Drug Carriers/chemistry
MH  - Drug Delivery Systems
MH  - Humans
MH  - Liposomes/chemistry/*pharmacology
MH  - Lung Neoplasms/*drug therapy
MH  - Mice
MH  - Mice, Nude
MH  - Particle Size
MH  - Peptides/chemistry
MH  - Phosphatidylethanolamines/chemistry
MH  - Polyethylene Glycols/chemistry/pharmacology
MH  - Xenograft Model Antitumor Assays/methods
EDAT- 2020/08/31 06:00
MHDA- 2021/02/10 06:00
CRDT- 2020/08/31 06:00
PHST- 2020/08/31 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2021/02/10 06:00 [medline]
PST - ppublish
SO  - J BUON. 2020 May-Jun;25(3):1504-1511.